A detailed history of Byrne Asset Management LLC transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Byrne Asset Management LLC holds 1,520 shares of ARCT stock, worth $25,596. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,520
Previous 1,840 17.39%
Holding current value
$25,596
Previous $44,000 43.18%
% of portfolio
0.02%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 28, 2025

SELL
$14.82 - $25.48 $4,742 - $8,153
-320 Reduced 17.39%
1,520 $25,000
Q3 2024

Jan 29, 2025

BUY
$18.08 - $25.38 $10,124 - $14,212
560 Added 36.84%
2,080 $48,000
Q3 2024

Jan 28, 2025

BUY
$18.08 - $25.38 $10,124 - $14,212
560 Added 36.84%
2,080 $48,000
Q2 2024

Jul 23, 2024

SELL
$24.35 - $44.39 $5,357 - $9,765
-220 Reduced 10.68%
1,840 $44,000
Q1 2024

Apr 22, 2024

SELL
$31.23 - $42.99 $8,432 - $11,607
-270 Reduced 11.59%
2,060 $69,000
Q4 2023

Jan 29, 2024

SELL
$17.71 - $32.97 $16,647 - $30,991
-940 Reduced 28.75%
2,330 $73,000
Q3 2023

Oct 31, 2023

SELL
$25.44 - $37.35 $5,851 - $8,590
-230 Reduced 6.57%
3,270 $83,000
Q2 2023

Jul 21, 2023

SELL
$23.94 - $32.36 $16,758 - $22,652
-700 Reduced 16.67%
3,500 $100,000
Q1 2023

Apr 17, 2023

SELL
$14.72 - $23.97 $34,076 - $55,490
-2,315 Reduced 35.53%
4,200 $100,000
Q4 2022

Jan 30, 2023

BUY
$14.14 - $23.06 $28,209 - $46,004
1,995 Added 44.14%
6,515 $110,000
Q3 2022

Oct 19, 2022

BUY
$13.05 - $22.13 $4,828 - $8,188
370 Added 8.92%
4,520 $67,000
Q2 2022

Jul 20, 2022

BUY
$12.26 - $31.17 $1,839 - $4,675
150 Added 3.75%
4,150 $74,000
Q1 2022

Apr 05, 2022

BUY
$17.64 - $39.57 $16,052 - $36,008
910 Added 29.45%
4,000 $108,000
Q4 2021

Feb 22, 2022

BUY
$34.2 - $47.56 $105,678 - $146,960
3,090 New
3,090 $114,000

Others Institutions Holding ARCT

About Arcturus Therapeutics Holdings Inc.


  • Ticker ARCT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,576,400
  • Market Cap $448M
  • Description
  • Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...
More about ARCT
Track This Portfolio

Track Byrne Asset Management LLC Portfolio

Follow Byrne Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Byrne Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Byrne Asset Management LLC with notifications on news.